Skip to main content

Advertisement

SpringerLink
Log in

Clinical evaluation of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (Filgrastim) for treatment of advanced breast cancer

  • ORIGINAL ARTICLE
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University Hospital, Utrecht, The Netherlands, , , , , , NL

    H. H. van Ojik  & Gerard Groenewegen

  2. Department of Immunology, University Hospital, Utrecht, The Netherlands, , , , , , NL

    Jan G. J. van de Winkel

  3. Division of Haematology/Oncology, Department of Medicine III, University of Erlangen-Nürnberg, Krankenhausstrasse 12, D-91054 Erlangen, Germany Tel. +49 9131 853434; Fax +49 9131 854770, , , , , , DE

    R. Repp & Thomas Valerius

Authors
  1. H. H. van Ojik 
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Repp
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gerard Groenewegen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas Valerius
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jan G. J. van de Winkel
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Accepted: 14 October 1997

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Ojik , H., Repp, R., Groenewegen, G. et al. Clinical evaluation of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (Filgrastim) for treatment of advanced breast cancer. Cancer Immunol Immunother 45, 207–209 (1997). https://doi.org/10.1007/s002620050434

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002620050434

Search

Navigation